Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins.
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Export pumps often limit the usefulness of anticancer drugs. Here we investigated the effect of cisplatin on the expression of ABC proteins in human colon cancer cells. Short-term incubation of Caco-2 and LS174T cells with cisplatin resulted in up-regulation of several ABC pumps, in particular MRP2 and BCRP. In partially cisplatin-resistant cells (LS174T/R) obtained by long-term exposure to cisplatin, MRP2 and BCRP up-regulation was more marked. This was further enhanced when these cells were cultured under maintained stimulation with cisplatin. The MRP2 promoter (MRP2pr) was cloned, and partially deleted constructs linked to reporter genes were generated. Transfection of LS174T and LS174T/R cells with these constructs revealed the ability of cisplatin to activate MRP2pr. The intensity of this response was dependent on the conserved MRP2pr region. Basal MRP2pr activity was higher in LS174T/R cells, in which the expression of the transcription factors c/EBPβ, HNF1α, HNF3β, and HNF4α, but not PXR, p53, c-Myc, AP1, YB-1, NRF2, and RARα was enhanced. Up-regulation was particularly high for FXR (200-fold) and SHP (50-fold). In LS174T/R cells, GW4064 induced the expression of FGF19, SHP, OSTα/β, but not MRP2 and BCRP, although the sensitivity of these cells to cisplatin was further reduced. In LS174T cells, GW4064-induced chemoresistance was seen only after being transfected with FXR+RXR, when BCRP, but not MRP2, was up-regulated. Protection of LS174T cells against cisplatin was mimicked by transfection with BCRP. In conclusion, in colon cancer cells, cisplatin treatment enhances chemoresistance through FXR-dependent and FXR-independent mechanisms involving the expression of BCRP and MRP2, respectively.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Markwell, M. A. K., Haas, S. M., Bieber, L. L., & Tolbert, N. E. (1978) · Analytical Biochemistry · doi:10.1016/0003-2697(78)90586-9 · Cited by 6,458
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., Tontonoz, P., Kliewer, S., Willson, T. M., & Edwards, P. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109326200 · Cited by 916
Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J., Juijn, J. A., Baas, F., & Borst, P. (1997) · PubMed · Cited by 882
Cisplatin and platinum drugs at the molecular level (Review)
Boulikas, T., & Vougiouka, M. (2003) · Oncology Reports · doi:10.3892/or.10.6.1663 · Cited by 729
Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53
Chin, K.-V., Ueda, K., Pastan, I., & Gottesman, M. M. (1992) · Science · doi:10.1126/science.1346476 · Cited by 726
Cui, Y., König, J., Buchholz, U., Spring, H., Leier, I., & Keppler, D. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23190-4 · Cited by 676
The apical conjugate efflux pump ABCC2 (MRP2)
Nies, A. T., & Keppler, D. (2007) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0109-y · Cited by 398
Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance.
Komatsu, M., Sumizawa, T., Mutoh, M., Chen, Z., Terada, K., Furukawa, T., Yang, X., Gao, H., Miura, N., Sugiyama, T., et al. (2000) · PubMed · Cited by 328
JEDLITSCHKY, G., LEIER, I., BUCHHOLZ, U., HUMMEL-EISENBEISS, J., BURCHELL, B., & KEPPLER, D. (1997) · Biochemical Journal · doi:10.1042/bj3270305 · Cited by 303
Koike, K., Kawabe, T., Tanaka, T., Toh, S., Uchiumi, T., Wada, M., Akiyama, S. I., Ono, M., & Kuwano, M. (1997) · PubMed · Cited by 249
Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene
Vollrath, V., Wielandt, A. M., Iruretagoyena, M., & Chianale, J. (2006) · Biochemical Journal · doi:10.1042/bj20051518 · Cited by 225
Feller, N., Broxterman, H. J., Währer, D. C. R., & Pinedo, H. M. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00677-2 · Cited by 192
Hinoshita, E., Uchiumi, T., Taguchi, K., Kinukawa, N., Tsuneyoshi, M., Maehara, Y., Sugimachi, K., & Kuwano, M. (2000) · PubMed · Cited by 179
Samimi, G., Varki, N. M., Wilczynski, S. P., Safaei, R., Alberts, D. S., & Howell, S. B. (2003) · PubMed · Cited by 139
Up-regulation of transporters of the MRP family by drugs and toxins
Schrenk, D., Baus, P. R., Ermel, N., Klein, C., Vorderstemann, B., & Kauffmann, H.-M. (2001) · Toxicology Letters · doi:10.1016/s0378-4274(01)00306-x · Cited by 125
Wang, Q., & Beck, W. T. (1998) · PubMed · Cited by 112
Kauffmann, H., KEPPLER, D. O. R., Kartenbeck, J., & Schrenk, D. (1997) · Hepatology · doi:10.1002/hep.510260427 · Cited by 104
Tanaka, T., Uchiumi, T., Hinoshita, E., Inokuchi, A., Toh, S., Wada, M., Takano, H., Kohno, K., & Kuwano, M. (1999) · Hepatology · doi:10.1002/hep.510300617 · Cited by 101
Kauffmann, H.-M., & Schrenk, D. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8340 · Cited by 93
Characterization of the Role of ABCG2 as a Bile Acid Transporter in Liver and Placenta
Blazquez, A. G., Briz, Ó., Romero, M. R., Rosales, R., Monte, M. J., Vaquero, J., Macı́as, R. I. R., Cassio, D., & Marı́n, J. J. G. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.075143 · Cited by 89
Self-citationPhosphorylation of Farnesoid X Receptor by Protein Kinase C Promotes Its Transcriptional Activity
Gineste, R., Sirvent, A., Paumelle, R., Helleboid, S., Aquilina, A., Darteil, R., Hum, D. W., Fruchart, J.-C., & Staels, B. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0092 · Cited by 79
Kauffmann, H.-M., KEPPLER, D. O. R., Gant, T. W., & Schrenk, D. (1998) · Archives of Toxicology · doi:10.1007/s002040050571 · Cited by 75
Mensah‐Osman, E., Thomas, D. G., Tabb, M. M., Larios, J. M., Hughes, D. P. M., Giordano, T. J., Lizyness, M. L., Rae, J. M., Blumberg, B., Hollenberg, P. F., et al. (2007) · Cancer · doi:10.1002/cncr.22479 · Cited by 73
Payen, L. F., Courtois, A., Loewert, M., Guillouzo, A., & Fardel, O. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4531 · Cited by 71
FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer
Sharif, S., O'Connell, M. J., Yothers, G., Lopa, S., & Wolmark, N. (2008) · Cancer Investigation · doi:10.1080/07357900802132550 · Cited by 70
Molecular Bases of Liver Cancer Refractoriness to Pharmacological Treatment
Marı́n, J. J. G., Romero, M. R., & Briz, Ó. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790514462 · Cited by 67
Self-citationTo, K. K. W., Yu, L., Liu, S., Fu, J., & Cho, C. H. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20810 · Cited by 65
Marin, J. J. G., Romero, M. R., Blazquez, A. G., Herraez, E., Keck, E., & Briz, O. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009787313828 · Cited by 58
Self-citationQadri, I., Iwahashi, M., Kullak-Ublick, G. A., & Simon, F. R. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023499 · Cited by 54
Fiorucci, S., Mencarelli, A., Cipriani, S., Renga, B., Palladino, G., Santucci, L., & Distrutti, E. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01481.x · Cited by 53
Briz, Ó., Macías, R. I. R., Vallejo, M., Silva, A., Serrano, M. A., & Marín, J. J. G. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.3.742 · Cited by 51
Self-citationLian, F., Xing, X., Yuan, G., Schäfer, C., Rauser, S., Walch, A. K., Röcken, C., Ebeling, M., Wright, M. B., Schmid, R. M., et al. (2011) · Biochemical Journal · doi:10.1042/bj20102096 · Cited by 49
Qadri, I., Hu, L., Iwahashi, M., Al-Zuabi, S., Quattrochi, L. C., & Simon, F. R. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.10.005 · Cited by 38
Vallejo, M., Castro, M. A., Medarde, M., Macı́as, R. I. R., Romero, M. R., El-Mir, M. Y., Monte, M. J., Briz, Ó., Serrano, M. A., & Marı́n, J. J. G. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.12.027 · Cited by 30
Self-citationPreoperative neo‐adjuvant therapy for curable rectal cancer – reaching a consensus 2008
Scott, N., Susnerwala, S. S., Gollins, S., Myint, A. S., & Levine, E. L. (2008) · Colorectal Disease · doi:10.1111/j.1463-1318.2008.01636.x · Cited by 26
Aleksunes, L. M., Yeager, R. L., & Klaassen, C. D. (2009) · Xenobiotica · doi:10.1080/00498250902952514 · Cited by 24
Monte, M. J., Ballestero, M. R., Briz, Ó., Perez, M. J., & Marı́n, J. J. G. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.086165 · Cited by 23
Functional analysis on the 5′-flanking region of human FXR gene in HepG2 cells
Lou, G., Li, Y., Chen, B., Chen, M., Chen, J., Liao, R., Zhang, Y., Wang, Y., & Zhou, D. (2007) · Gene · doi:10.1016/j.gene.2007.04.011 · Cited by 13
Research works printed but not linked: 8
- Boulikas T., 2003, Oncol. Rep., 10, 1663
- Samimi G., 2003, Clin. Cancer Res., 9, 5853
- Komatsu M., 2000, Cancer Res., 60, 1312
- Hinoshita E., 2000, Clin. Cancer Res., 6, 2401
- Kool M., 1997, Cancer Res., 57, 3537
- Koike K., 1997, Cancer Res., 57, 5475
- Wang Q., 1998, Cancer Res., 58, 5762
- To K. K., 2011, Mol. Carcinog., 51, 449
Cited by
Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Hu, T., Li, Z., Gao, C.-Y., & Cho, C. H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6876 · Cited by 381
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Vaquero, J., Monte, M. J., Domínguez, M., Muntané, J., & Marín, J. J. G. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.022 · Cited by 139
“In this respect, it is noteworthy that FXR-dependent expression of target genes involved in chemoresistance are different in intestinal (ABCC2 and ABCG2) [14] and liver (ABCB4, TCEA2, CCL14, CCL15 and KRT13) [15] cells.”
BackgroundSelf-citationMultidrug efflux transporter ABCG2: expression and regulation
Kukal, S., Guin, D., Rawat, C., Bora, S., Mishra, M., Sharma, P., Paul, P. R., Kanojia, N., Grewal, G. K., Kukreti, S., et al. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03901-y · Cited by 139
Nuclear bile acid signaling through the farnesoid X receptor
Mazuy, C., Helleboid‐Chapman, A., Staels, B., & Lefèbvre, P. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1805-y · Cited by 122
“[145, 146] reported that FXR activation stimulates the chemoprotection of hepatocytes against genotoxic compounds, thus reducing the response of tumor cells to pharmacologically induced cellular toxicity in vitro.”
Background
Metadata
- Authors
- Herraez, E., Gonzalez-Sanchez, E., Vaquero, J., Romero, M. R., Serrano, M. A., Marin, J. J. G., & Briz, O.
- Affiliations
- Laboratory of Experimental Hepatology and Drug Targeting (HEVEFARM), Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca, Spain
- Universidad de Salamanca (ES)
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-08-01
- Volume
- 9
- Issue
- 9
- Pages
- 2565-2576
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2092149794
- Cited by
- 67
- References
- 42
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 1 · 2023: 6 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 5 · 2016: 7 · 2015: 5 · 2014: 8 · 2013: 8 · 2012: 2
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Gredos (University of Salamanca) (acceptedVersion, cc-by-nc-nd)
- Hispana (acceptedVersion, cc-by-nc-nd)
- Funders
- Instituto de Salud Carlos III
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- cisplatin, chemoresistance, colon cancer, ABC transporters, MRP2, ABCG2, farnesoid X receptor, SHP, transcriptional activation, HNF4α, HNF1A, FGF19, GW4064, Caco-2 cells, LS174T cells
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily G, Member 2, Receptor, Farnesoid X-Activated, Cisplatin, Colonic Neoplasms, DNA-Binding Proteins, Humans, Microfilament Proteins, Neoplasm Proteins, Promoter Regions, Genetic, Transcription Factors, Transfection, Transcriptional Activation, Up-Regulation, Gene Expression, Genes, Reporter, Receptors, Cytoplasmic and Nuclear, ATP-Binding Cassette Transporters, Caco-2 Cells, Drug Resistance, Neoplasm, Cell Line, Tumor, Hep G2 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.